Kudos to @nucleusgenomics for sponsoring this IRB study testing whether screening embryos based on polygenic risk scores will decrease implantation rates compared to screening only on embryo morphology!
Many IVF programs treat the ASRM Opinion as a guideline for polygenic embryo selection. I’m pleased to announce the launch of PRISM (Polygenic Risk-Informed Selection versus Morphology), one of the largest clinical studies of polygenic embryo analysis to date. More in thread.
Many IVF programs treat the ASRM Opinion as a guideline for polygenic embryo selection. I’m pleased to announce the launch of PRISM (Polygenic Risk-Informed Selection versus Morphology), one of the largest clinical studies of polygenic embryo analysis to date. More in thread.
I welcome discussion with others working in reproductive medicine, genetics, and embryology, including those with different perspectives on the clinical application of polygenic risk information.
For anyone interested in learning more about PRISM, participating in the study, or discussing opportunities for collaboration, please reach out at prism@mynucleus.com.
Study registration: ClinicalTrials.gov (NCT07841769)
PRISM is a non-inferiority clinical trial evaluating whether incorporating polygenic risk estimates into embryo selection affects implantation rates vs. conventional morphology-based selection. Published clinical outcome data on this remain limited.
I welcome discussion with others working in reproductive medicine, genetics, and embryology, including those with different perspectives on the clinical application of polygenic risk information.
For anyone interested in learning more about PRISM, participating in the study, or discussing opportunities for collaboration, please reach out at prism@mynucleus.com.
Study registration: ClinicalTrials.gov (NCT07841769)
Thank you @ENBrown for the insightful piece.
Like when I talked with the Times, we are now one step closer to giving more people a path to parenthood, and that definitely is something to celebrate.